Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laborit study of sodium oxybate for lorazepam-resistant catatonia
NL-OMON54182Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in catatonia comparing Continued high-dose lorazepam with Sodium oxybate (2 arms). Primary endpoint: Response rate after 4 days of randomized treatment. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
sodium oxybatelorazepam
03
Conditions
catatonia
Beyond the preview
Go deeper on NL-OMON54182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54182.